Mahendra Patel

Zydus Pharmaceuticals (USA), Inc. is a globally integrated generic pharmaceutical company. It manufactures tablets, capsules, soft gel, sterile liquids, injectables, inhalers, topicals, and trans-dermal patch dosage forms. The firm's products include generic name, brand equipment, dosage form, and therapeutic category. The company was founded in August 2005 and is headquartered in Pennington, NJ.

Zydus Pharmaceuticals (USA), Inc. is a globally integrated generic pharmaceutical company. It manufactures tablets, capsules, soft gel, sterile liquids, injectables, inhalers, topicals, and trans-dermal patch dosage forms. The firm's products include generic name, brand equipment, dosage form, and therapeutic category. The company was founded in August 2005 and is headquartered in Pennington, NJ.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.

Zydus Pharmaceuticals (USA), Inc. is a globally integrated generic pharmaceutical company. It manufactures tablets, capsules, soft gel, sterile liquids, injectables, inhalers, topicals, and trans-dermal patch dosage forms. The firm's products include generic name, brand equipment, dosage form, and therapeutic category. The company was founded in August 2005 and is headquartered in Pennington, NJ.

Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India.